ELSEVIER

Journal of Affective Disorders 61 (2000) 257–258

JOURNAL OF AFFECTIVE DISORDERS

www.elsevier.com/locate/jad

Author index

Abajian, H., see Feighner, J.P. (61) 119
Alda, M., see Grof, P. (61) 31

Baker, G.B., see Sherry, R.L. (61) 23
Baldessarini, R.J., Tondo, L., Floris, G. and Hennen, J.
Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients (61) 13
Barefoot, J.C., see Brummett, B.H. (61) 41
Barlow, D., see Van den Hout, M. (61) 241
Beekman, A.T.F., see Penninx, B.W.J.H. (61) 1
Benazzi, F.
Early-onset versus late-onset atypical depression: unipolar and bipolar II (61) 95
Berghoefer, A., see Grof, P. (61) 31
Borrero, G., see Friberg, T.R. (61) 113
Bourne, M.L., see Strakowski, S.M. (61) 87
Brummett, B.H., Barefoot, J.C., Siegler, I.C. and Steffens, D.C.
Relation of subjective and received social support to clinical and self-report assessments of depressive symptoms in an elderly population (61) 41

Camardese, G., see Sarchiapone, M. (61) 69
Cardascia, L., see Preti, A. (61) 101
Carter, J.D., Joyce, P.R., Mulder, R.T., Luty, S.E. and McKenzie, J.
Gender differences in the presentation of depressed outpatients: a comparison of descriptive variables (61) 59
Cooke, R.G., see Kusznir, A. (61) 81
Coutts, R.T., see Sherry, R.L. (61) 23

Davis, M., see Lang, P.J. (61) 137
Deeg, D.J.H., see Penninx, B.W.J.H. (61) 1
DelBello, M.P., see Strakowski, S.M. (61) 87
Denda, K., see Izumi, T. (61) 127
De Risio, S., see Sarchiapone, M. (61) 69

Ehrensing, R.H., see Feighner, J.P. (61) 119
Eiring, A., see Manier, D.H. (61) 51
Ellis, T.C., see Manier, D.H. (61) 51

Favaretto, G., see Preti, A. (61) 101
Feighner, J.P., Ehrensing, R.H., Kastin, A.J., Leonard, B.E., Sverdlov, L., Nicolau, G., Patel, A., Hlavka, J., Abajian, H. and Noble, J.F.
A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression (61) 119
Fermanian, J., see Guedeney, N. (61) 107
Fleck, D.E., see Strakowski, S.M. (61) 87
Floris, G., see Baldessarini, R.J. (61) 13
Fowles, D.C.
Electrodermal hyporeactivity and antisocial behavior: does anxiety mediate the relationship? (61) 177
Friberg, T.R. and Borrero, G.
Diminished perception of ambient light: a symptom of clinical depression? (61) 113

Glaudin, V., see Londborg, P.D. (61) 73
Gorman, J.M., see Sinha, S. (61) 191
Gray, J.A., see McNaughton, N. (61) 161
Grof, P., Robbins, W., Alda, M., Berghoefer, A., Vojtechovsky, M., Nilsson, A. and Robertson, C.
Protective effect of pregnancy in women with lithium-responsive bipolar disorder (61) 31
Guedeney, N., Fermanian, J., Guelfi, J.D. and Kumar, R.C.
The Edinburgh Postnatal Depression Scale (EPDS) and the detection of major depressive disorders in early postpartum: some concerns about false negatives (61) 107
Guelfi, J.D., see Guedeney, N. (61) 107
Guralnik, J.M., see Penninx, B.W.J.H. (61) 1

Hennen, J., see Baldessarini, R.J. (61) 13
Hlavka, J., see Feighner, J.P. (61) 119
Hoehn-Saric, R. and McLeod, D.R.
Anxiety and arousal: physiological changes and their perception (61) 217

Inoue, T., see Izumi, T. (61) 127
Izumi, T., Inoue, T., Kitagawa, N., Nishi, N., Shimanaka, S., Takahashi, Y., Kusumi, I., Odagaki, Y., Denda, K., Ohmori, T. and Koyama, T.
Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression (61) 127

Joyce, P.R., see Carter, J.D. (61) 59

Kastin, A.J., see Feighner, J.P. (61) 119
Kitagawa, N., see Izumi, T. (61) 127

S0165-0327(00)00376-1

Koyama, T., see Izumi, T. (61) 127
Kumar, R.C., see Guedeney, N. (61) 107
Kusumi, I., see Izumi, T. (61) 127
Kusznir, A., Cooke, R.G. and Young, L.T.
The correlates of community functioning in patients with bipolar disorder (61) 81

Lane, R.D., see Thayer, J.F. (61) 201
Lang, P. and Maser, J.D.
Editorial (61) 133
Lang, P.J., Davis, M. and Öhman, A.
Fear and anxiety: animal models and human cognitive psychophysiology (61) 137
Leonard, B.E., see Feighner, J.P. (61) 119
Londborg, P.D., Smith, W.T., Glaudin, V. and Painter, J.R.
Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression (61) 73
Luty, S.E., see Carter, J.D. (61) 59

Manier, D.H., Shelton, R.C., Ellis, T.C., Peterson, C.S., Eiring, A. and Sulser, F.
Human fibroblasts as a relevant model to study signal transduction in affective disorders (61) 51
Marchetti, M., see Preti, A. (61) 101
Maser, J.D., see Lang, P. (61) 133
McKenna, K.F., see Sherry, R.L. (61) 23
McKenzie, J., see Carter, J.D. (61) 59
McLeod, D.R., see Hoehn-Saric, R. (61) 217
McNaughton, N. and Gray, J.A.
Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety (61) 161
Miotto, P., see Preti, A. (61) 101
Mulder, R.T., see Carter, J.D. (61) 59

Nicolau, G., see Feighner, J.P. (61) 119
Nilsson, A., see Grof, P. (61) 31
Nishi, N., see Izumi, T. (61) 127
Noble, J.F., see Feighner, J.P. (61) 119

Odagaki, Y., see Izumi, T. (61) 127
Öhman, A., see Lang, P.J. (61) 137
Ohmori, T., see Izumi, T. (61) 127
Orr, S.P. and Roth, W.T.
Psychophysiological assessment: clinical applications for PTSD (61) 225

Paetsch, P.R., see Sherry, R.L. (61) 23
Painter, J.R., see Londborg, P.D. (61) 73
Papp, L.A., see Sinha, S. (61) 191
Patel, A., see Feighner, J.P. (61) 119
Pellizzari, P., see Preti, A. (61) 101
Penninx, B.W.J.H., Deeg, D.J.H., van Eijk, J.Th.M., Beekman, A.T.F. and Guralnik, J.M.
Changes in depression and physical decline in older adults: a longitudinal perspective (61) 1
Peterson, C.S., see Manier, D.H. (61) 51
Preti, A., Cardascia, L., Zen, T., Pellizzari, P., Marchetti, M., Favaretto, G. and Miotto, P.
Obstetric complications in patients with depression — a population-based case–control study (61) 101

Rauw, G., see Sherry, R.L. (61) 23
Robbins, W., see Grof, P. (61) 31
Robertson, C., see Grof, P. (61) 31
Roth, W.T., see Orr, S.P. (61) 225
Roy, A., see Sarchiapone, M. (61) 69

Sarchiapone, M., Roy, A., Camardese, G. and De Risio, S.
Further evidence for low serum cholesterol and suicidal behaviour (61) 69
Sax, K.W., see Strakowski, S.M. (61) 87
Shelton, R.C., see Manier, D.H. (61) 51
Sherry, R.L., Rauw, G., McKenna, K.F., Paetsch, P.R., Coutts, R.T. and Baker, G.B.
Failure to detect amphetamine or 1-amino-3-phenlypropane in humans or rats receiving the MAO inhibitor tranylcypromine (61) 23
Shimanaka, S., see Izumi, T. (61) 127
Siegler, I.C., see Brummett, B.H. (61) 41
Sinha, S., Papp, L.A. and Gorman, J.M.
How study of respiratory physiology aided our understanding of abnormal brain function in panic disorder (61) 191
Smith, W.T., see Londborg, P.D. (61) 73
Steffens, D.C., see Brummett, B.H. (61) 41
Strakowski, S.M., Williams, J.R., Sax, K.W., Fleck, D.E., DelBello, M.P. and Bourne, M.L.
Is impaired outcome following a first manic episode due to mood-incongruent psychosis? (61) 87
Sulser, F., see Manier, D.H. (61) 51
Sverdlov, L., see Feighner, J.P. (61) 119

Takahashi, Y., see Izumi, T. (61) 127
Thayer, J.F. and Lane, R.D.
A model of neurovisceral integration in emotion regulation and dysregulation (61) 201
Tondo, L., see Baldessarini, R.J. (61) 13

van den Hout, M. and Barlow, D.
Attention, arousal and expectancies in anxiety and sexual disorders (61) 241
van Eijk, J.Th.M., see Penninx, B.W.J.H. (61) 1
Vojtechovsky, M., see Grof, P. (61) 31

Williams, J.R., see Strakowski, S.M. (61) 87

Young, L.T., see Kusznir, A. (61) 81

Zen, T., see Preti, A. (61) 101

ELSEVIER

Journal of Affective Disorders 61 (2000) 259–261

JOURNAL OF AFFECTIVE DISORDERS

www.elsevier.com/locate/jad

Subject index

1-Amino-3-phenylpropane; Amphetamine; Electron-capture gas chromatography; Metabolism; Pentafluorobenzenesulfonyl chloride; Tranylcypromine **61,** 23

Amphetamine; 1-Amino-3-phenylpropane; Electron-capture gas chromatography; Metabolism; Pentafluorobenzenesulfonyl chloride; Tranylcypromine **61,** 23

Animal models; Fear; Anxiety; Startle-reflex; Psychophysiology; Defense motivation **61,** 137

Antidepressants; Peptides; Serotonin **61,** 119

Anxiety; Pregnancy; Bipolar disorder; Placenta; Postpartum depression **61,** 31

Anxiety; Human fibroblasts; Beta adrenoceptors; Cyclic AMP; Isoproterenol; Protein kinase A (PKA); CREB-P; Luciferase activity **61,** 51

Anxiety; Gender; Symptomatology; Characteristics **61,** 59

Anxiety; Clonazepam; Cotherapy; Fluoxetine; Side-effects (drug); Drug therapy; Augmentation **61,** 73

Anxiety; Community functioning; Comorbid alcohol abuse **61,** 81

Anxiety; Atypical; Bipolar **61,** 95

Anxiety; Brain damage; Gestational; obstetric complications **61,** 101

Anxiety; Arousal; Generalized anxiety disorder; Behavioural inhibition system; Anxiolytic; Septo-hippocampal system; Hippocampus; Theta activity; Theta rhythm **61,** 161

Anxiety; Psychopathy; Electrodermal; Skin conductance; Behavioral inhibition system; Impulsivity **61,** 177

Anxiety; Sexual disorder; Dysfunctional; Selective attention **61,** 241

Anxiety; Fear; Startle-reflex; Psychophysiology; Animal models; Defense motivation **61,** 137

Anxiolytic; Anxiety; Arousal; Generalized anxiety disorder; Behavioural inhibition system; Septo-hippocampal system; Hippocampus; Theta activity; Theta rhythm **61,** 161

Arousal; Anxiety; Generalized anxiety disorder; Behavioural inhibition system; Anxiolytic; Septo-hippocampal system; Hippocampus; Theta activity; Theta rhythm **61,** 161

Assessment; Post-traumatic stress disorder; Psychophysiological findings; Clinical application **61,** 225

Atypical; Depression; Bipolar **61,** 95

Augmentation; Clonazepam; Cotherapy; Fluoxetine; Major depression; Side-effects (drug); Drug therapy **61,** 73

Behavioral inhibition system; Psychopathy; Electrodermal; Skin conductance; Impulsivity; Anxiety **61,** 177

Behavioural inhibition system; Anxiety; Arousal; Generalized anxiety disorder; Anxiolytic; Septo-hippocampal system; Hippocampus; Theta activity; Theta rhythm **61,** 161

Beta adrenoceptors; Human fibroblasts; Major depression; Cyclic AMP; Isoproterenol; Protein kinase A (PKA); CREB-P; Luciferase activity **61,** 51

Biopolar disorder; Mood-incongruent psychosis; DSM-IV; Schizoaffactive disorder **61,** 87

Bipolar; Depression; Atypical **61,** 95

Bipolar disorder; Pregnancy; Placenta; Lithium; Postpartum depression **61,** 31

Bipolar I and II disorders; Illness course; Lithium; Rapid cycling **61,** 13

Brain damage; Depression; Gestational; obstetric complications **61,** 101

Characteristics; Depression; Gender; Symptomatology **61,** 59

Clinical application; Post-traumatic stress disorder; Psychophysiological findings; Assessment **61,** 225

Clonazepam; Cotherapy; Fluoxetine; Major depression; Side-effects (drug); Drug therapy; Augmentation **61,** 73

Community functioning; Bipolar disorder; Comorbid alcohol abuse **61,** 81

Comorbid alcohol abuse; Bipolar disorder; Community functioning **61,** 81

Cotherapy; Clonazepam; Fluoxetine; Major depression; Side-effects (drug); Drug therapy; Augmentation **61,** 73

CREB-P; Human fibroblasts; Major depression; Beta adrenoceptors; Cyclic AMP; Isoproterenol; Protein kinase A (PKA); Luciferase activity **61,** 51

S0165-0327(00)00377-7

Cyclic AMP; Human fibroblasts; Major depression; Beta adrenoceptors; Isoproterenol; Protein kinase A (PKA); CREB-P; Luciferase activity **61,** 51

Defense motivation; Fear; Anxiety; Startle-reflex; Psychophysiology; Animal models **61,** 137

Depression; Physical decline; Older adults **61,** 1

Depressive symptoms; Subjective social support; Received social support **61,** 41

Dim light; Perception of light; Major depression **61,** 113

Disorder; Physiological flexibility; Perception of somatic symptoms; Generalized anxiety; Panic disorder; Obsessive-compulsive disorder; Somatic symptoms **61,** 217

Dopamine; Pergolide; Refractory depression; Treatment-resistant depression **61,** 127

Drug therapy; Clonazepam; Cotherapy; Fluoxetine; Major depression; Side-effects (drug); Augmentation **61,** 73

DSM-IV; Mood-incongruent psychosis; Biopolar disorder; Schizoaffactive disorder **61,** 87

Dysfunctional; Anxiety; Sexual disorder; Selective attention **61,** 241

Electrodermal; Psychopathy; Skin conductance; Behavioral inhibition system; Impulsivity; Anxiety **61,** 177

Electron-capture gas chromatography; 1-Amino-3-phenylpropane; Amphetamine; Metabolism; Pentafluorobenzenesulfonyl chloride; Tranylcypromine **61,** 23

Emotion regulation and dysregulation; Neurovisceral integration **61,** 201

EPDS; Post natal depression; False negative; Psychomotor retardation **61,** 107

False negative; Post natal depression; EPDS; Psychomotor retardation **61,** 107

Fear; Anxiety; Startle-reflex; Psychophysiology; Animal models; Defense motivation **61,** 137

Fluoxetine; Clonazepam; Cotherapy; Major depression; Side-effects (drug); Drug therapy; Augmentation **61,** 73

Gender; Depression; Symptomatology; Characteristics **61,** 59

Generalized anxiety disorder; Anxiety; Arousal; Behavioural inhibition system; Anxiolytic; Septo-hippocampal system; Hippocampus; Theta activity; Theta rhythm **61,** 161

Generalized anxiety; Physiological flexibility; Perception of somatic symptoms; Disorder; Panic disorder; Obsessive-compulsive disorder; Somatic symptoms **61,** 217

Gestational; Brain damage; Depression; obstetric complications **61,** 101

Hippocampus; Anxiety; Arousal; Generalized anxiety disorder; Behavioural inhibition system; Anxiolytic; Septo-hippocampal system; Theta activity; Theta rhythm **61,** 161

Human fibroblasts; Major depression; Beta adrenoceptors; Cyclic AMP; Isoproterenol; Protein kinase A (PKA); CREB-P; Luciferase activity **61,** 51

Hyperventilation; Respiration physiology; Panic attacks **61,** 191

Illness course; Bipolar I and II disorders; Lithium; Rapid cycling **61,** 13

Impulsivity; Psychopathy; Electrodermal; Skin conductance; Behavioral inhibition system; Anxiety **61,** 177

Isoproterenol; Human fibroblasts; Major depression; Beta adrenoceptors; Cyclic AMP; Protein kinase A (PKA); CREB-P; Luciferase activity **61,** 51

Lithium; Bipolar I and II disorders; Illness course; Rapid cycling **61,** 13

Luciferase activity; Human fibroblasts; Major depression; Beta adrenoceptors; Cyclic AMP; Isoproterenol; Protein kinase A (PKA); CREB-P **61,** 51

Major depression; Perception of light; Dim light **61,** 113

Metabolism; 1-Amino-3-phenylpropane; Amphetamine; Electron-capture gas chromatography; Pentafluorobenzenesulfonyl chloride; Tranylcypromine **61,** 23

Mood-incongruent psychosis; Biopolar disorder; DSM-IV; Schizoaffactive disorder **61,** 87

Neurovisceral integration; Emotion regulation and dysregulation **61,** 201

Obsessive-compulsive disorder; Physiological flexibility; Perception of somatic symptoms; Generalized anxiety; Disorder; Panic disorder; Somatic symptoms **61,** 217

obstetric complications; Brain damage; Depression; Gestational **61,** 101

Older adults; Depression; Physical decline **61,** 1

Panic attacks; Respiration physiology; Hyperventilation **61,** 191

Panic disorder; Physiological flexibility; Perception of somatic symptoms; Generalized anxiety; Disorder; Obsessive-compulsive disorder; Somatic symptoms **61,** 217

Pentafluorobenzenesulfonyl chloride; 1-Amino-3-phenylpropane; Amphetamine; Electron-capture gas chromatography; Metabolism; Tranylcypromine **61,** 23

Peptides; Antidepressants; Serotonin **61,** 119

Perception of light; Dim light; Major depression **61,** 113

Perception of somatic symptoms; Physiological flexibility; Generalized anxiety; Disorder; Panic disorder; Obsessive-compulsive disorder; Somatic symptoms **61,** 217

Pergolide; Dopamine; Refractory depression; Treatment-resistant depression **61,** 127

Physical decline; Depression; Older adults **61,** 1

Physiological flexibility; Perception of somatic symptoms;

Generalized anxiety; Disorder; Panic disorder; Obsessive-compulsive disorder; Somatic symptoms **61,** 217

Placenta; Pregnancy; Bipolar disorder; Lithium; Postpartum depression **61,** 31

Post natal depression; EPDS; False negative; Psychomotor retardation **61,** 107

Postpartum depression; Pregnancy; Bipolar disorder; Placenta; Lithium **61,** 31

Post-traumatic stress disorder; Psychophysiological findings; Clinical application; Assessment **61,** 225

Pregnancy; Bipolar disorder; Placenta; Lithium; Postpartum depression **61,** 31

Protein kinase A (PKA); Human fibroblasts; Major depression; Beta adrenoceptors; Cyclic AMP; Isoproterenol; CREB-P; Luciferase activity **61,** 51

Psychomotor retardation; Post natal depression; EPDS; False negative **61,** 107

Psychopathy; Electrodermal; Skin conductance; Behavioral inhibition system; Impulsivity; Anxiety **61,** 177

Psychophysiological findings; Post-traumatic stress disorder; Clinical application; Assessment **61,** 225

Psychophysiology; Fear; Anxiety; Startle-reflex; Animal models; Defense motivation **61,** 137

Rapid cycling; Bipolar I and II disorders; Illness course; Lithium **61,** 13

Received social support; Depressive symptoms; Subjective social support **61,** 41

Refractory depression; Pergolide; Dopamine; Treatment-resistant depression **61,** 127

Relationship; Serum cholesterol; Suicidal behavior **61,** 69

Respiration physiology; Hyperventilation; Panic attacks **61,** 191

Schizoaffactive disorder; Mood-incongruent psychosis; Biopolar disorder; DSM-IV **61,** 87

Selective attention; Anxiety; Sexual disorder; Dysfunctional **61,** 241

Septo-hippocampal system; Anxiety; Arousal; Generalized anxiety disorder; Behavioural inhibition system; Anxiolytic; Hippocampus; Theta activity; Theta rhythm **61,** 161

Serotonin; Antidepressants; Peptides **61,** 119

Serum cholesterol; Suicidal behavior; Relationship **61,** 69

Sexual disorder; Anxiety; Dysfunctional; Selective attention **61,** 241

Side-effects (drug); Clonazepam; Cotherapy; Fluoxetine; Major depression; Drug therapy; Augmentation **61,** 73

Skin conductance; Psychopathy; Electrodermal; Behavioral inhibition system; Impulsivity; Anxiety **61,** 177

Somatic symptoms; Physiological flexibility; Perception of somatic symptoms; Generalized anxiety; Disorder; Panic disorder; Obsessive-compulsive disorder **61,** 217

Startle-reflex; Fear; Anxiety; Psychophysiology; Animal models; Defense motivation **61,** 137

Subjective social support; Depressive symptoms; Received social support **61,** 41

Suicidal behavior; Serum cholesterol; Relationship **61,** 69

Symptomatology; Depression; Gender; Characteristics **61,** 59

Theta activity; Anxiety; Arousal; Generalized anxiety disorder; Behavioural inhibition system; Anxiolytic; Septo-hippocampal system; Hippocampus; Theta rhythm **61,** 161

Theta rhythm; Anxiety; Arousal; Generalized anxiety disorder; Behavioural inhibition system; Anxiolytic; Septo-hippocampal system; Hippocampus; Theta activity **61,** 161

Tranylcypromine; 1-Amino-3-phenylpropane; Amphetamine; Electron-capture gas chromatography; Metabolism; Pentafluorobenzenesulfonyl chloride **61,** 23

Treatment-resistant depression; Pergolide; Dopamine; Refractory depression **61,** 127